Floatz logo

Peg-L-Asparaginase

T-Cell Lymphoma

Dana-Farber Cancer InstituteEarly Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

85 Active assets in the T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
GC Cell Corporation
Phase 2BBB
Brentuximab Vedotin
Yale University
Phase 4BBB
cc-5013
Samsung Medical Center
Phase 2BB
Cyclophosphamide
GC Cell Corporation
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Memorial Sloan Kettering Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Peg-L-Asparaginase is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
55 / 100
View asset →
mixed phenotype acute leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →